At present, the Post Operative Therapy with Endocrine and TS-1 (POTENT) trial, a randomized, controlled, phase III study of postoperative chemotherapy in patients with ER-positive, HER2-negative breast cancer, is ongoing. This evidence concerns the gene ESR1 and breast cancer.